PRESS RELEASE published on 09/04/2024 at 22:15, 1 year 6 months ago NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth Nanobiotix announces key additions to Supervisory Board - Dr. Margaret A. Liu & Ms. Anat Naschitz. Expertise to drive growth in nanophysics-based therapies for cancer & major diseases Supervisory Board NANOBIOTIX Dr. Margaret A. Liu Ms. Anat Naschitz Nanophysics-based Therapies
BRIEF published on 09/03/2024 at 22:20, 1 year 6 months ago Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference Biotechnology Webcast Fireside Chat NANOBIOTIX Investment Conference
PRESS RELEASE published on 09/03/2024 at 22:15, 1 year 6 months ago Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference Nanobiotix to present at H.C. Wainwright 26th Annual Global Investment Conference. Company management to participate in fireside chat on September 11, 2024 Biotechnology Cancer H.C. Wainwright NANOBIOTIX Global Investment Conference
BRIEF published on 08/08/2024 at 22:20, 1 year 7 months ago Nanobiotix: Information on Voting Rights and Shares as of July 31, 2024 Share Capital Voting Rights Actions Sotck Exchange NANOBIOTIX
PRESS RELEASE published on 08/08/2024 at 22:15, 1 year 7 months ago Voting Rights and Shares Capital of the Company Nanobiotix announces monthly publication of voting rights and shares capital in compliance with French Commercial Code. Learn more about the company's disruptive biotechnology approaches Voting Rights French Commercial Code Biotechnology Shares Capital NANOBIOTIX
BRIEF published on 07/09/2024 at 22:20, 1 year 8 months ago Voting Rights and Shares Capital of Nanobiotix Voting Rights Shares Euronext Nasdaq NANOBIOTIX
PRESS RELEASE published on 07/09/2024 at 22:15, 1 year 8 months ago Voting Rights and Shares Capital of the Company Nanobiotix discloses voting rights and shares capital information as per French Commercial Code. Check the latest figures for June 30, 2024 Euronext Paris Voting Rights French Commercial Code Shares Capital NANOBIOTIX
BRIEF published on 07/03/2024 at 15:54, 1 year 8 months ago Threshold crossings at NANOBIOTIX by Goldman Sachs Group AMF Goldman Sachs NANOBIOTIX Threshold Crossings
BRIEF published on 06/12/2024 at 22:20, 1 year 9 months ago Nanobiotix hosts virtual discussion on the potential of NBTXR3 in cancer treatments Immunotherapy Head And Neck Cancer NANOBIOTIX NBTXR3 Virtual Discussion
PRESS RELEASE published on 06/12/2024 at 22:15, 1 year 9 months ago NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 Nanobiotix to host virtual KOL event discussing NBTXR3 combined with immunotherapy in head and neck cancer and beyond on June 18, 2024 Immunotherapy Head And Neck Cancer NANOBIOTIX NBTXR3 Virtual KOL Event
Published on 03/26/2026 at 23:00, 14 minutes ago FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 1 hour 9 minutes ago BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 1 hour 14 minutes ago Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 1 hour 14 minutes ago Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 2 hours 14 minutes ago Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 20:48, 2 hours 26 minutes ago Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 3 hours 54 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 4 hours 4 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:17, 4 hours 57 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 07:30, 15 hours 44 minutes ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
